Synergistic interaction between risk burden and genetics for atrial fibrillation development
1. In a large prospective study, risk burden and genetic predisposition acted synergistically to...
Read MoreMar 22, 2023
1. In a large prospective study, risk burden and genetic predisposition acted synergistically to...
Read MoreMar 20, 2023
1. In this meta-analysis, it was found that the pooled prevalence of sleep-related breathing...
Read MoreMar 20, 2023
1. Localized prostate cancer mortality remains similar between groups receiving prostatectomy,...
Read MoreMar 20, 2023
1. There is a 71% lower risk of disease progression or death in the nirogacestat group than in the...
Read MoreMar 20, 2023
1. In this systematic review and meta-analysis, both exercise and caloric restriction were...
Read MoreMar 20, 2023
1. Patients allocated to the sotorasib group reported increased progression-free survival compared...
Read MoreMar 20, 2023
1. In this prospective cohort study, age was found to be the most prominent risk factor for the...
Read MoreMar 20, 2023
1. Etranacogene dezaparvovec gene therapy was more effective than prophylactic factor IX infusion...
Read MoreMar 20, 2023
1. The mean eGFR slope was comparable among patients allocated to sodium bicarbonate and placebo...
Read MoreMar 20, 2023
1. In this randomized controlled trial, ultrasound ablation of the globus pallidus was associated...
Read MoreMar 20, 2023
1. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) in combination with standard of care were...
Read MoreMar 20, 2023
1. Patients receiving secukinumab every 2-weeks showed superior clinical response rates compared...
Read MoreMar 20, 2023
1. In this retrospective cohort study, Black patients with pulmonary fibrosis (PF) were found to...
Read MoreMar 20, 2023
1. In this randomized control trial, an eight-week bedaquiline-linezolid regimen was noninferior...
Read MoreMar 20, 2023
1. In this retrospective cohort study, two-thirds of incidental pituitary microadenomas remained...
Read MoreMar 12, 2023
1. Compared to alisertib alone, adding alisertib to fulvestrant did not increase objective tumour...
Read MoreMar 10, 2023
1. Mandated and available paid-sick-leave resulted in increased colorectal and breast cancer...
Read MoreMar 10, 2023
1. Event-free survival at 2 years was longer in the neoadjuvant-adjuvant group vs the...
Read MoreMar 10, 2023
1. In a retrospective cohort study, the implementation of policies to strengthen nutritional...
Read MoreMar 10, 2023
1. In this sham-controlled, randomized clinical trial, among 224 patients with hypertension,...
Read More